Novobiocin Explained

Novobiocin, also known as albamycin, is an aminocoumarin antibiotic that is produced by the actinomycete Streptomyces niveus, which has recently been identified as a subjective synonym for S. spheroides[1] a member of the class Actinomycetia. Other aminocoumarin antibiotics include clorobiocin and coumermycin A1.[2] Novobiocin was first reported in the mid-1950s (then called streptonivicin).[3] [4]

Clinical use

It is active against Staphylococcus epidermidis and may be used to differentiate it from the other coagulase-negative Staphylococcus saprophyticus, which is resistant to novobiocin, in culture.

Novobiocin was licensed for clinical use under the tradename Albamycin (Upjohn) in the 1960s. Its efficacy has been demonstrated inpreclinical and clinical trials.[5] [6] The oral form of the drug has since been withdrawn from the market due to lack of efficacy.[7] A combination product of novobiocin and tetracycline, sold by Upjohn under brand names such as Panalba and Albamycin-T, was in particular the subject of intense FDA scrutiny before it was finally taken off the market.[8] [9] Novobiocin is an effective antistaphylococcal agent used in the treatment of MRSA.[10]

Mechanism of action

The molecular basis of action of novobiocin, and other related drugs clorobiocin and coumermycin A1 has been examined.[2] [11] [12] [13] [14] Aminocoumarins are very potent inhibitors of bacterial DNA gyrase and work by targeting the GyrB subunit of the enzyme involved in energy transduction. Novobiocin as well as the other aminocoumarin antibiotics act as competitive inhibitors of the ATPase reaction catalysed by GyrB. The potency of novobiocin is considerably higher than that of the fluoroquinolones that also target DNA gyrase, but at a different site on the enzyme. The GyrA subunit is involved in the DNA nicking and ligation activity.

Novobiocin has been shown to weakly inhibit the C-terminus of the eukaryotic Hsp90 protein (high micromolar IC50). Modification of the novobiocin scaffold has led to more selective Hsp90 inhibitors.[15] Novobiocin has also been shown to bind and activate the Gram-negative lipopolysaccharide transporter LptBFGC.[16] [17]

The ATP binding pocket of polymerase theta is blocked by novobiocin resulting in a loss of ATPase activity. This results in the loss of microhomology-mediated end joining as a pathway for homologous recombination deficient cells to circumvent DNA damaging agents. The action of novobiocin is syngeristic with PARP inhibitors for reducing tumor size in a mouse model. [18]

Structure

Novobiocin is an aminocoumarin. Novobiocin may be divided up into three entities; a benzoic acid derivative, a coumarin residue, and the sugar novobiose.[11] X-ray crystallographic studies have found that the drug-receptor complex of Novobiocin and DNA Gyrase shows that ATP and Novobiocin have overlapping binding sites on the gyrase molecule.[19] The overlap of the coumarin and ATP-binding sites is consistent with aminocoumarins being competitive inhibitors of the ATPase activity.[20]

Structure–activity relationship

In structure activity relationship experiments it was found that removal of the carbamoyl group located on the novobiose sugar lead to a dramatic decrease in inhibitory activity of novobiocin.[20]

Biosynthesis

This aminocoumarin antibiotic consists of three major substituents. The 3-dimethylallyl-4-hydroxybenzoic acid moiety, known as ring A, is derived from prephenate and dimethylallyl pyrophosphate. The aminocoumarin moiety, known as ring B, is derived from L-tyrosine. The final component of novobiocin is the sugar derivative L-noviose, known as ring C, which is derived from glucose-1-phosphate. The biosynthetic gene cluster for novobiocin was identified by Heide and coworkers in 1999 (published 2000) from Streptomyces spheroides NCIB 11891.[21] They identified 23 putative open reading frames (ORFs) and more than 11 other ORFs that may play a role in novobiocin biosynthesis.

The biosynthesis of ring A (see Fig. 1) begins with prephenate which is a derived from the shikimic acid biosynthetic pathway. The enzyme NovF catalyzes the decarboxylation of prephenate while simultaneously reducing nicotinamide adenine dinucleotide phosphate (NADP+) to produce NADPH. Following this NovQ catalyzes the electrophilic substitution of the phenyl ring with dimethylallyl pyrophosphate (DMAPP) otherwise known as prenylation.[22] DMAPP can come from either the mevalonic acid pathway or the deoxyxylulose biosynthetic pathway. Next the 3-dimethylallyl-4-hydroxybenzoate molecule is subjected to two oxidative decarboxylations by NovR and molecular oxygen.[23] NovR is a non-heme iron oxygenase with a unique bifunctional catalysis. In the first stage both oxygens are incorporated from the molecular oxygen while in the second step only one is incorporated as determined by isotope labeling studies. This completes the formation of ring A.

The biosynthesis of ring B (see Fig. 2) begins with the natural amino acid L-tyrosine. This is then adenylated and thioesterified onto the peptidyl carrier protein (PCP) of NovH by ATP and NovH itself.[24] NovI then further modifies this PCP bound molecule by oxidizing the β-position using NADPH and molecular oxygen. NovJ and NovK form a heterodimer of J2K2 which is the active form of this benzylic oxygenase.[25] This process uses NADP+ as a hydride acceptor in the oxidation of the β-alcohol. This ketone will prefer to exist in its enol tautomer in solution. Next a still unidentified protein catalyzes the selective oxidation of the benzene (as shown in Fig. 2). Upon oxidation this intermediate will spontaneously lactonize to form the aromatic ring B and lose NovH in the process.

The biosynthesis of L-noviose (ring C) is shown in Fig. 3. This process starts from glucose-1-phosphate where NovV takes dTTP and replaces the phosphate group with a dTDP group. NovT then oxidizes the 4-hydroxy group using NAD+. NovT also accomplishes a dehydroxylation of the 6 position of the sugar. NovW then epimerizes the 3 position of the sugar.[26] The methylation of the 5 position is accomplished by NovU and S-adenosyl methionine (SAM). Finally NovS reduces the 4 position again to achieve epimerization of that position from the starting glucose-1-phosphate using NADH.

Rings A, B, and C are coupled together and modified to give the finished novobiocin molecule. Rings A and B are coupled together by the enzyme NovL using ATP to diphosphorylate the carboxylate group of ring A so that the carbonyl can be attacked by the amine group on ring B. The resulting compound is methylated by NovO and SAM prior to glycosylation.[27] NovM adds ring C (L-noviose) to the hydroxyl group derived from tyrosine with the loss of dTDP. Another methylation is accomplished by NovP and SAM at the 4 position of the L-noviose sugar.[28] This methylation allows NovN to carbamylate the 3 position of the sugar as shown in Fig. 4 completing the biosynthesis of novobiocin.

External links

Notes and References

  1. Lanoot B, Vancanneyt M, Cleenwerck I, Wang L, Li W, Liu Z, Swings J . The search for synonyms among streptomycetes by using SDS-PAGE of whole-cell proteins. Emendation of the species Streptomyces aurantiacus, Streptomyces cacaoi subsp. cacaoi, Streptomyces caeruleus and Streptomyces violaceus . International Journal of Systematic and Evolutionary Microbiology . 52 . Pt 3 . 823–9 . May 2002 . 12054245 . 10.1099/00207713-52-3-823 .
  2. da Silva Eustáquio A . Ph.D. . Universität Tübingen . 2004 . Biosynthesis of aminocoumarin antibiotics in Streptomyces: Generation of structural analogues by genetic engineering and insights into the regulation of antibiotic production .
  3. Hoeksema H, Johnson JL, Hinman JW . December 1955 . Structural studies on streptonivicin, a new antibiotic . Journal of the American Chemical Society . 77 . 24. 6710–6711 . 10.1021/ja01629a129.
  4. Smith CG, Dietz A, Sokolski WT, Savage GM . Streptonivicin, a new antibiotic. I. Discovery and biologic studies . Antibiotics & Chemotherapy . 6 . 2 . 135–142 . February 1956 . 24543916 .
  5. Raad I, Darouiche R, Hachem R, Sacilowski M, Bodey GP . Antibiotics and prevention of microbial colonization of catheters . Antimicrobial Agents and Chemotherapy . 39 . 11 . 2397–400 . November 1995 . 8585715 . 162954 . 10.1128/aac.39.11.2397 .
  6. Raad II, Hachem RY, Abi-Said D, Rolston KV, Whimbey E, Buzaid AC, Legha S . A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2 . Cancer . 82 . 2 . 403–11 . January 1998 . 9445199 . 10.1002/(SICI)1097-0142(19980115)82:2<412::AID-CNCR22>3.0.CO;2-0 . 10940970 .
  7. Web site: Determination That ALBAMYCIN (Novobiocin Sodium) Capsule, 250 Milligrams, Was Withdrawn From Sale for Reasons of Safety or Effectiveness . 19 January 2011 . The Federal Register .
  8. Mintz M . FDA and Panalba: A Conflict of Commercial, Therapeutic Goals? . EN . Science . 165 . 3896 . 875–881 . August 1969 . 10.1126/science.165.3896.875 . 5819616 . 1969Sci...165..875M .
  9. Web site: Mintz M . Upjohn's Shuck and Jive Routine . Mother Jones . Mother Jones and the Foundation for National Progress . 16 February 2022.
  10. Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, Montgomerie JZ, Goetz MB, Mayhall CG, Rimland D . Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome . Antimicrobial Agents and Chemotherapy . 37 . 6 . 1334–42 . June 1993 . 8328783 . 187962 . 10.1128/aac.37.6.1334 .
  11. Maxwell A . The interaction between coumarin drugs and DNA gyrase . Molecular Microbiology . 9 . 4 . 681–6 . August 1993 . 8231802 . 10.1111/j.1365-2958.1993.tb01728.x . 43159068 .
  12. Maxwell A . DNA gyrase as a drug target . Biochemical Society Transactions . 27 . 2 . 48–53 . February 1999 . 10093705 . 10.1042/bst0270048 .
  13. Lewis RJ, Tsai FT, Wigley DB . Molecular mechanisms of drug inhibition of DNA gyrase . BioEssays . 18 . 8 . 661–71 . August 1996 . 8760340 . 10.1002/bies.950180810 . 9488669 .
  14. Maxwell A, Lawson DM . The ATP-binding site of type II topoisomerases as a target for antibacterial drugs . Current Topics in Medicinal Chemistry . 3 . 3 . 283–303 . 2003 . 12570764 . 10.2174/1568026033452500 .
  15. Yu XM, Shen G, Neckers L, Blake H, Holzbeierlein J, Cronk B, Blagg BS . Hsp90 inhibitors identified from a library of novobiocin analogues . Journal of the American Chemical Society . 127 . 37 . 12778–9 . September 2005 . 16159253 . 10.1021/ja0535864 .
  16. Mandler MD, Baidin V, Lee J, Pahil KS, Owens TW, Kahne D . Novobiocin Enhances Polymyxin Activity by Stimulating Lipopolysaccharide Transport . Journal of the American Chemical Society . 140 . 22 . 6749–6753 . June 2018 . 29746111 . 5990483 . 10.1021/jacs.8b02283 .
  17. May JM, Owens TW, Mandler MD, Simpson BW, Lazarus MB, Sherman DJ, Davis RM, Okuda S, Massefski W, Ruiz N, Kahne D . The Antibiotic Novobiocin Binds and Activates the ATPase That Powers Lipopolysaccharide Transport . EN . Journal of the American Chemical Society . 139 . 48 . 17221–17224 . December 2017 . 29135241 . 5735422 . 10.1021/jacs.7b07736 .
  18. Zhou J, Gelot C, Pantelidou C, Li A, Yücel H, Davis RE, Färkkilä A, Kochupurakkal B, Syed A, Shapiro GI, Tainer JA, Blagg BS, Ceccaldi R, D'Andrea AD . A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors . EN . Nature Cancer . 2 . June 2021 . 598–610 . June 2021 . 34179826. 10.1038/s43018-021-00203-x. 8224818 . 235659640 .
  19. Tsai FT, Singh OM, Skarzynski T, Wonacott AJ, Weston S, Tucker A, Pauptit RA, Breeze AL, Poyser JP, O'Brien R, Ladbury JE, Wigley DB . The high-resolution crystal structure of a 24-kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin . Proteins . 28 . 1 . 41–52 . May 1997 . 9144789 . 10.1002/(sici)1097-0134(199705)28:1<41::aid-prot4>3.3.co;2-b .
  20. Flatman RH, Eustaquio A, Li SM, Heide L, Maxwell A . Structure-activity relationships of aminocoumarin-type gyrase and topoisomerase IV inhibitors obtained by combinatorial biosynthesis . Antimicrobial Agents and Chemotherapy . 50 . 4 . 1136–42 . April 2006 . 16569821 . 1426943 . 10.1128/AAC.50.4.1136-1142.2006 .
  21. Steffensky M, Mühlenweg A, Wang ZX, Li SM, Heide L . Identification of the novobiocin biosynthetic gene cluster of Streptomyces spheroides NCIB 11891 . Antimicrobial Agents and Chemotherapy . 44 . 5 . 1214–22 . May 2000 . 10770754 . 89847 . 10.1128/AAC.44.5.1214-1222.2000 .
  22. Pojer F, Wemakor E, Kammerer B, Chen H, Walsh CT, Li SM, Heide L . CloQ, a prenyltransferase involved in clorobiocin biosynthesis . Proceedings of the National Academy of Sciences of the United States of America . 100 . 5 . 2316–21 . March 2003 . 12618544 . 151338 . 10.1073/pnas.0337708100 . 2003PNAS..100.2316P . free .
  23. Pojer F, Kahlich R, Kammerer B, Li SM, Heide L . CloR, a bifunctional non-heme iron oxygenase involved in clorobiocin biosynthesis . The Journal of Biological Chemistry . 278 . 33 . 30661–8 . August 2003 . 12777382 . 10.1074/jbc.M303190200 . free .
  24. Chen H, Walsh CT . Coumarin formation in novobiocin biosynthesis: beta-hydroxylation of the aminoacyl enzyme tyrosyl-S-NovH by a cytochrome P450 NovI . Chemistry & Biology . 8 . 4 . 301–12 . April 2001 . 11325587 . 10.1016/S1074-5521(01)00009-6 . free .
  25. Pacholec M, Hillson NJ, Walsh CT . NovJ/NovK catalyze benzylic oxidation of a beta-hydroxyl tyrosyl-S-pantetheinyl enzyme during aminocoumarin ring formation in novobiocin biosynthesis . Biochemistry . 44 . 38 . 12819–26 . September 2005 . 16171397 . 10.1021/bi051297m . 10.1.1.569.1481 .
  26. Thuy TT, Lee HC, Kim CG, Heide L, Sohng JK . Functional characterizations of novWUS involved in novobiocin biosynthesis from Streptomyces spheroides . Archives of Biochemistry and Biophysics . 436 . 1 . 161–7 . April 2005 . 15752721 . 10.1016/j.abb.2005.01.012 .
  27. Pacholec M, Tao J, Walsh CT . CouO and NovO: C-methyltransferases for tailoring the aminocoumarin scaffold in coumermycin and novobiocin antibiotic biosynthesis . Biochemistry . 44 . 45 . 14969–76 . November 2005 . 16274243 . 10.1021/bi051599o .
  28. Freel Meyers CL, Oberthür M, Xu H, Heide L, Kahne D, Walsh CT . Characterization of NovP and NovN: completion of novobiocin biosynthesis by sequential tailoring of the noviosyl ring . Angewandte Chemie . 43 . 1 . 67–70 . January 2004 . 14694473 . 10.1002/anie.200352626 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Novobiocin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.